Findings Conflicted for Benefit of Tocilizumab in COVID-19
One trial shows reduction in mortality, but no evidence of efficacy seen in two additional trials
Survival From COVID-19 High in Patients With Psoriasis
Risk for hospitalization increased for patients using nonbiologic systemic therapy versus biologics
Convalescent Plasma Has Limited Benefit for Moderate COVID-19
Randomized phase II trial shows no drop in progression to severe disease, all-cause deaths
Skin Breaks Drop With Prolonged AL/CVL Use in Neonates
Larger thalamic volumes seen with prolonged arterial line, central venous line use and fewer skin breaks
Cytokines Not at ‘Storm’ Levels in Those With Severe COVID-19
Levels in severely, critically ill COVID-19 patients much lower than in other inflammatory syndromes
Algorithm Predicts Death, Hospital Admission From COVID-19
Final risk algorithm includes age, ethnicity, deprivation, body mass index, range of comorbidities
Tocilizumab Does Not Prevent Intubation, Death in COVID-19
Intubation or death, disease worsening similar for tocilizumab, placebo in hospitalized patients
CDC: Number of COVID-19 Deaths May Be Underreported
Only two-thirds of the nearly 300,000 excess deaths in 2020 are attributed to COVID-19
U.S. COVID-19 Vaccine Trial Enrolls 30,000
Moderna says it is on track to apply for FDA approval to market the vaccine in early December
CDC Broadens Definition of ‘Close Contact’ in Tracing COVID-19 Infections
Change will likely have biggest impact in group settings where people are in repeated contact with others
